There is a significant need for novel HIV therapies given the emergence of viruses resistant to existing drug regimens. RNA-protein complexes represent an important and under utilized drug target. In HIV, the Tat-TAR and Rev-RRE RNA- protein complexes carry out essential roles in RNA transcription and nuclear export respectively. Disruption of these RNA-protein complexes can inhibit viral replication, thus this strategy holds great promise for antiviral drug discovery. Advanced Genetic Systems (AGS) and UCSF have jointly developed a cell- based drug-screening platform to target RNA and RNA-protein complexes. The screening platform was rigorously evaluated with control inhibitors and a pilot screen of 4500 small molecule compounds targeting Rev-RRE. From this screen, we identified novel compounds that specifically target Rev, exhibit low toxicity, display favorable pharmacokinetic properties, and inhibit HIV replication at sub-micromolar IC50s. This result has given us great confidence that we have developed a high-quality, robust screening platform capable of identifying inhibitors of viral RNA-protein targets. We now wish to use our screening platform to carry out expanded screens targeting HIV Rev- RRE and Tat-TAR. We will screen a small molecule diversity library to identify new molecular entities that could form the basis of new classes of anti-HIV therapeutics. ? ?

Public Health Relevance

There is significant need to develop new classes of antiviral drugs to combat emerging viral diseases and resistance to older drugs. RNA-protein complexes represent an important and under utilized viral drug target. Disruption of an RNA-protein complex can inhibit viral replication, thus this strategy holds great promise for antiviral drug discovery. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43AI076143-01A1
Application #
7494932
Study Section
Special Emphasis Panel (ZRG1-AARR-E (16))
Program Officer
Miller, Roger H
Project Start
2008-03-01
Project End
2010-08-31
Budget Start
2008-03-01
Budget End
2010-08-31
Support Year
1
Fiscal Year
2008
Total Cost
$238,974
Indirect Cost
Name
Advanced Genetic Systems, Inc.
Department
Type
DUNS #
154446921
City
San Francisco
State
CA
Country
United States
Zip Code
94122
Nakamura, Robert L; Burlingame, Mark A; Yang, Shumin et al. (2017) Identification and Optimization of Thienopyridine Carboxamides as Inhibitors of HIV Regulatory Complexes. Antimicrob Agents Chemother 61: